[go: up one dir, main page]

PE57898A1 - Derivados de sulfonil urea - Google Patents

Derivados de sulfonil urea

Info

Publication number
PE57898A1
PE57898A1 PE1998000051A PE00005198A PE57898A1 PE 57898 A1 PE57898 A1 PE 57898A1 PE 1998000051 A PE1998000051 A PE 1998000051A PE 00005198 A PE00005198 A PE 00005198A PE 57898 A1 PE57898 A1 PE 57898A1
Authority
PE
Peru
Prior art keywords
alkyl
rent
formula
group
zero
Prior art date
Application number
PE1998000051A
Other languages
English (en)
Inventor
Mark Anthony Dombroski
James Frederick Eggler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE57898A1 publication Critical patent/PE57898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) o SU SAL, DONDE R1 ES (C1-C6)ALQUILO OPCIONALMENTE SUSTITUIDO POR (C1-C6)ALQUILAMINO, (C1-C6)ALQUILTIO, ENTRE OTROS; R1 Y R2 SON a)UN GRUPO DE FORMULA (II); n ES 0-3; "A, B, D, E Y G" SON O, S, N o CR5R6, R5 Y R6 SON H, (C1-C6)ALQUILO, OPCIONALMENTE SUSTITUIDO POR (C1-C6)ALQUILAMINO, (C1-C6)ALQUILTIO, ENTRE OTROS; b)UN GRUPO DE FORMULA (III), s ES CERO-6, t ES CERO-1; "X" ES O o NR8, R8 ES H, (C1-C6)ALQUILO o (C3-C7)CICLOALQUIL(C1-C6)ALQUILO; "Y" ES H, OH, (C1-C6)ALQUILO OPCIONALMENTE SUSTITUIDO POR HALO, OH, CN, ENTRE OTROS; c)UN GRUPO DE LA FORMULA (IV), u ES CERO-2, R19 ES H, (C1-C6)ALQUILO o PERFLUORO(C1-C6)ALQUILO; R20 ES H, (C1-C6)ALQUILO, (C1-C6)CARBOXIALQUILO d)UN GRUPO DE FORMULA (V), a Y e SON 0-2, b Y d SON 0-1, c ES 1-3; "J Y L" SON O o S; R21 ES H, OH, F, ENTRE OTROS; R22 ES H, (C1-C6)ALQUILO OPCIONALMENTE SUSTITUIDO POR OH, HALO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS 4-(1-HIDROXI-1-METIL-ETIL)-FURAN-2-SULFONAMIDA; 1-(4-CLORO-2,6 DIISOPROPIL-FENIL)-3-[3-(1-HIDROXI-1-METIL-ETIL)BENCENOSULFONIL]UREA; ENTRE OTROS. EL COMPUESTO I INHIBE LA TRANSFORMACION Y LIBERACION DE INTERLEUCINA-1O E INTERLEUCINA-1�. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE LA MENINGITIS, SALPINGITIS, CHOQUE SEPTICO, COAGULACION INTRAVASCULAR DISEMINADA
PE1998000051A 1997-01-29 1998-01-23 Derivados de sulfonil urea PE57898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3697997P 1997-01-29 1997-01-29

Publications (1)

Publication Number Publication Date
PE57898A1 true PE57898A1 (es) 1999-06-11

Family

ID=21891776

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000051A PE57898A1 (es) 1997-01-29 1998-01-23 Derivados de sulfonil urea

Country Status (40)

Country Link
US (2) US6166064A (es)
EP (1) EP0964849B1 (es)
JP (1) JP3573757B2 (es)
KR (1) KR100324058B1 (es)
CN (1) CN1127479C (es)
AP (1) AP929A (es)
AR (1) AR011093A1 (es)
AT (2) ATE242208T1 (es)
AU (1) AU723895B2 (es)
BG (1) BG103597A (es)
BR (1) BR9714328A (es)
CA (1) CA2279186C (es)
CO (1) CO4920230A1 (es)
CZ (1) CZ293173B6 (es)
DE (2) DE69722663T2 (es)
DK (2) DK0964849T3 (es)
DZ (1) DZ2407A1 (es)
EA (1) EA001803B1 (es)
ES (2) ES2198598T3 (es)
HR (1) HRP980045B1 (es)
HU (1) HUP0000567A3 (es)
ID (1) ID22223A (es)
IL (1) IL130855A0 (es)
IS (1) IS5099A (es)
MA (1) MA26468A1 (es)
NO (1) NO313279B1 (es)
NZ (1) NZ336248A (es)
OA (1) OA11079A (es)
PA (1) PA8444701A1 (es)
PE (1) PE57898A1 (es)
PL (1) PL335052A1 (es)
PT (2) PT1270565E (es)
SK (1) SK283679B6 (es)
TN (1) TNSN98017A1 (es)
TR (1) TR199901816T2 (es)
TW (1) TW515788B (es)
UY (1) UY24861A1 (es)
WO (1) WO1998032733A1 (es)
YU (1) YU33799A (es)
ZA (1) ZA98685B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022984A (en) * 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (en) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulfonylurea binding proteins
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
BR0014003A (pt) * 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
CA2459454A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
EP1487457A1 (en) * 2001-11-30 2004-12-22 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
RU2236677C2 (ru) * 2002-06-24 2004-09-20 Чичкова Марина Александровна Способ прогнозирования раннего клинического течения экссудативного перикардита у больных с системными заболеваниями
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
CN101628939B (zh) 2002-09-06 2014-06-25 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
AU2003263560A1 (en) * 2002-10-03 2004-04-23 Pfizer Products Inc. Use of gst-omega-2 as a therapeutic target
JP5036310B2 (ja) 2003-08-06 2012-09-26 セノミックス インコーポレイテッド 新規な風味、風味改質剤、味覚剤、味覚向上剤、旨味および甘味味覚剤、および／またはそれらの向上剤および使用
AU2005223402B2 (en) * 2004-03-23 2011-07-21 Dompe' Farmaceutici S.P.A. 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
TWI375521B (en) 2005-02-04 2012-11-01 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
CA2957566C (en) 2014-08-12 2023-08-01 Daniel Paul Becker Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
HUE055755T2 (hu) * 2015-02-16 2021-12-28 Univ Queensland Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
WO2016138473A1 (en) * 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
EP3872070A1 (en) 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3445749B1 (en) * 2016-04-18 2022-12-21 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
EP3548480A1 (en) * 2016-11-29 2019-10-09 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
AU2018210525B2 (en) 2017-01-23 2022-06-02 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
AU2017416068A1 (en) * 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
US11236045B2 (en) 2017-06-09 2022-02-01 Cadila Healthcare Limited Substituted sulfoximine compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
CN120647572A (zh) 2017-07-07 2025-09-16 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
FI3658539T3 (fi) 2017-07-24 2024-05-16 Novartis Ag Yhdisteitä ja koostumuksia nlrp-aktiivisuuteen liittyvien tilojen hoitamiseksi
PE20200758A1 (es) 2017-08-15 2020-07-27 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
MX2020001778A (es) 2017-08-15 2020-03-24 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
EP3692020A1 (en) 2017-10-03 2020-08-12 Inflazome Limited Novel compounds
WO2019079119A1 (en) * 2017-10-17 2019-04-25 IFM Tre, Inc. SULFONAMIDES AND ASSOCIATED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
US12012392B2 (en) 2017-11-09 2024-06-18 Inflazome Limited Sulfonamide carboxamide compounds
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN108299256B (zh) * 2018-01-09 2019-09-10 武汉大学 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
WO2019166633A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759078A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
CN112584899A (zh) * 2018-07-03 2021-03-30 诺华股份有限公司 Nlrp调节剂
MX2021000660A (es) 2018-07-20 2021-03-25 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
WO2020018975A1 (en) 2018-07-20 2020-01-23 Genentech, Inc. Sulfonimidamide compounds as inhibitors of interleukin-1 activity
EP3836954B1 (en) 2018-08-13 2025-05-07 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
KR20210053910A (ko) 2018-08-15 2021-05-12 인플라좀 리미티드 신규한 설폰아마이드유레아 화합물
WO2020086732A1 (en) 2018-10-24 2020-04-30 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
EA202191968A1 (ru) 2019-01-14 2021-11-16 Кадила Хелзкэр Лимитед Новые замещенные производные сульфонилмочевины
JP7682813B2 (ja) 2019-06-12 2025-05-26 ノッドセラ リミテッド スルホニル尿素誘導体及びその使用
EP3986879B1 (en) 2019-06-21 2024-10-02 AC Immune SA Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
JP2022548869A (ja) 2019-09-12 2022-11-22 カディラ・ヘルスケア・リミテッド 新規な置換スルホキシミン誘導体
US12428391B2 (en) 2020-06-11 2025-09-30 Cisen Pharmaceutical Co., Ltd Dimethylsulfoximine derivative
BR112022025612A2 (pt) 2020-06-19 2023-01-17 Ac Immune Sa Derivados de di-hidro-oxazol e tioureia modulando a via do inflamassoma nlrp3
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
AU2021336518A1 (en) 2020-09-04 2023-03-23 NodThera Limited Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
CN118355000A (zh) * 2021-12-03 2024-07-16 辰欣药业股份有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
JP2025502732A (ja) 2021-12-22 2025-01-28 エーシー・イミューン・エス・アー ジヒドロオキサゾール誘導体化合物
MX2024009770A (es) * 2022-02-15 2024-08-19 Hoffmann La Roche Procesos para la preparacion de derivados de 1,2,3,5,6,7-hexahidro -s-indaceno.
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CN119907802A (zh) 2022-07-14 2025-04-29 Ac免疫有限公司 作为nlrp3炎症小体通路调节剂的吡咯并三嗪和咪唑并三嗪衍生物
AU2023313032A1 (en) 2022-07-28 2025-01-23 Ac Immune Sa Novel compounds
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586950A (en) * 1982-05-31 1986-05-06 E. I. Du Pont De Nemours & Company Novel phenyl-substituted sulfonamides
US4780125A (en) * 1982-09-01 1988-10-25 Ciba-Geigy Corporation N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) * 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) * 1994-12-07 1998-06-10 南开大学 磺酰脲类化合物及其除草用途
HU226462B1 (en) * 1995-02-17 2008-12-29 Hoechst Ag Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
WO1998044799A1 (en) * 1997-04-10 1998-10-15 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea

Also Published As

Publication number Publication date
EA001803B1 (ru) 2001-08-27
DE69729762D1 (de) 2004-08-05
NO993658L (no) 1999-09-28
BG103597A (bg) 2000-02-29
HRP980045A2 (en) 1999-06-30
AP9801190A0 (en) 1998-03-31
AU5234098A (en) 1998-08-18
NO313279B1 (no) 2002-09-09
CN1245490A (zh) 2000-02-23
SK283679B6 (sk) 2003-11-04
BR9714328A (pt) 2000-03-21
EA199900603A1 (ru) 2000-02-28
PT1270565E (pt) 2004-09-30
CO4920230A1 (es) 2000-05-29
HUP0000567A3 (en) 2002-10-28
ATE270285T1 (de) 2004-07-15
DE69722663T2 (de) 2004-04-29
ATE242208T1 (de) 2003-06-15
HRP980045B1 (en) 2002-10-31
CN1127479C (zh) 2003-11-12
DE69729762T2 (de) 2005-07-14
WO1998032733A1 (en) 1998-07-30
TW515788B (en) 2003-01-01
HUP0000567A2 (hu) 2000-10-28
TR199901816T2 (xx) 1999-11-22
JP3573757B2 (ja) 2004-10-06
ES2198598T3 (es) 2004-02-01
US6433009B1 (en) 2002-08-13
UY24861A1 (es) 2000-09-29
AU723895B2 (en) 2000-09-07
PT964849E (pt) 2003-08-29
AR011093A1 (es) 2000-08-02
EP0964849B1 (en) 2003-06-04
US6166064A (en) 2000-12-26
CZ293173B6 (cs) 2004-02-18
PA8444701A1 (es) 2000-05-24
DK1270565T3 (da) 2004-10-04
NO993658D0 (no) 1999-07-28
ES2222426T3 (es) 2005-02-01
CA2279186C (en) 2004-02-24
KR100324058B1 (ko) 2002-02-16
AP929A (en) 2001-01-18
NZ336248A (en) 2000-10-27
MA26468A1 (fr) 2004-12-20
DZ2407A1 (fr) 2003-01-04
CA2279186A1 (en) 1998-07-30
DE69722663D1 (de) 2003-07-10
OA11079A (en) 2002-03-14
JP2000511200A (ja) 2000-08-29
IS5099A (is) 1999-06-29
CZ257599A3 (cs) 2000-09-13
TNSN98017A1 (fr) 2005-03-15
KR20000070541A (ko) 2000-11-25
DK0964849T3 (da) 2003-08-25
SK98299A3 (en) 2001-10-08
EP0964849A1 (en) 1999-12-22
PL335052A1 (en) 2000-03-27
ID22223A (id) 1999-09-16
YU33799A (sh) 2002-03-18
ZA98685B (en) 1999-07-29
IL130855A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
PE57898A1 (es) Derivados de sulfonil urea
ES2173172T3 (es) Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina.
BG95344A (bg) Фунгицидни оксазолидинони
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
ATE144253T1 (de) Methanoanthracene als dopaminantagonisten
ATE146780T1 (de) Verbindungen mit guanidin-struktur und diese enthaltende pharmazeutische zusammensetzungen
FI923664A0 (fi) Piperidinderivat.
DE69229738D1 (de) Antiseborrhoische zusammensetzung
DK0705112T3 (da) Sammensætninger til deodorisering af animalske ekskrementer og dertil hørende fremgangsmåde til deodorisering
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
MX170951B (es) Composicion antimicrobiana y metodo de uso
DE60121459D1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
MX9301627A (es) Agente para utilizarse como un antiirritante y composicion que lo contiene.
HU9202641D0 (en) Method for producing methano-anthracene derivatives and pharmaceutical preparatives containing said compounds as active substance
ATE12335T1 (de) Anwendung von o-phenyl-hydroxylamin und bestimmte derivate davon als pflanzenwachstumsfaktoren.
AU2002100152B4 (en) Parasiticide composition
BR8702878A (pt) Composicoes,processo de tratamento de plantas para combater infeccao microbicida na planta,compostos,processo para a preparacao dos ditos compostos e composicoes e material de propagacao de plantas cultivadas
DE68903893D1 (de) 20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.
TH13275A (th) สารต่อต้านการออกซิไดส์ชนิดใหม่

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed